Last reviewed · How we verify

NCT04236882

Sleep and Physical Activity Intervention for Increasing Physical Activity in Overweight or Obese and Sedentary African Americans

Active, enrolled NA Last updated 17 February 2026
What this trial tests

NA trial testing Focus Group in Behavioral Disorder in 28 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 October 2019
Primary endpoint
30 April 2030
30 April 2030

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposesupportive care
Enrollment28
Start date4 October 2019
Primary completion30 April 2030
Estimated completion30 April 2030
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 21 to 65, any sex, with Behavioral Disorder or Endocrine System Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well sleep and physical activity interventions work in increasing the physical activity of overweight or obese and sedentary African Americans. Sleep and physical activity interventions may help to increase physical activity among overweight and obese African American adults who do not get enough exercise.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Focus Group

Trials testing the same drug.

Other recruiting trials for Behavioral Disorder

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04236882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing